Gum Arabic as Antioxidant and Anti-inflammatory in Hemodialysis Patients

• Register: ClinicalTrials.gov
• Last refreshed on: 16 December 2017
• Main ID: NCT03214692
• Date of registration: 18/06/2017
• Prospective Registration: Yes
• Primary sponsor: Lamis Kaddam
• Public title: Gum Arabic as Antioxidant and Anti-inflammatory in Hemodialysis Patients GA&CRF
• Scientific title: Potential Role of Gum Arabic as Antioxidant and Anti-inflammatory Agent in Hemodialysis Patients
• Date of first enrolment: July 2017
• Target sample size: 50
• Recruitment status: Enrolling by invitation
• URL: https://clinicaltrials.gov/show/NCT03214692
• Study type: Interventional
• Study design: Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
• Phase: N/A

Countries of recruitment

Sudan

Key inclusion & exclusion criteria

Inclusion Criteria:

- End stage renal disease patients on regular hemodialysis.

Exclusion Criteria:

- Patient known have ischemic heart disease (coronary artery disease),

- Pregnant women,

- Patient who have impaired liver function or hepatitis VIRUS positive,

- Patient who HIV positive and patient currently use of GUM Arabic.



Age minimum: 18 Years
Age maximum: 80 Years
Gender: All

Health Condition(s) or Problem(s) studied

End-Stage Renal Disease

Intervention(s)

Dietary Supplement: Gum Arabic

Primary Outcome(s)

Change from baseline Oxidative stress marker malondialdehyde [Time Frame: Baseline and after 12 weeks]

Change from baseline Tumor necrosis factor alpha [Time Frame: Baseline and after 12 weeks]

Secondary Outcome(s)

Glomerular Filtration Rate (GFR) [Time Frame: Baseline and every four weeks for 12 weeks]

Secondary ID(s)

GA&CRF

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

University of Khartoum

Military Hospital Sudan